

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

This Amendment to a Current Report on Form 8-K/A supplements the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 29, 2018 regarding the election of Richard Zoretic to the board of directors of Molina Healthcare, Inc. (the “Company”) on May 25, 2018.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 16, 2018, Richard Zoretic was appointed to the Audit Committee and the Compliance Committee of the board of directors of the Company, effective August 1, 2018. In addition to Mr. Zoretic’s standard compensation amounts payable to non-executive directors of the Company, Mr. Zoretic will also receive \$15,000 annually for his service on the Audit Committee and \$12,500 annually for his service on the Compliance Committee, all as described in the Company’s definitive proxy statement filed with the SEC on March 19, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MOLINA HEALTHCARE, INC.

Date: July 17, 2018 By: */s/ Jeff D. Barlow*
Jeff D. Barlow
Chief Legal Officer and Secretary